US Edition
News from Pharmaphorum
If you want to know if Pharmaphorum is credible or reliable, look no further. We rank Pharmaphorum as High factuality. Find out more about our methodology here.
Media Bias Ratings
Average Bias Rating:
Center
Center
byAd Fontes MediaDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Pharmaphorum News
DiabetesNovo Nordisk A/S (NYSE:NVO) on Monday shared headline results from the REIMAGINE 2 phase 3 trial from the global REIMAGINE clinical trial program. CagriSema for weight management was submitted to the U.S. Food and Drug Administration (FDA) in December 2025 based on the REDEFINE 1 and REDEFINE 2 pivotal trials. Trial Data REIMAGINE 2 was a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination…See the Story
Novo Nordisk's Next-Gen Combination Drug Beats Semaglutide in Weight Loss and Blood Sugar Control - Novo Nordisk (NYSE:NVO)
80% Center coverage: 5 sources
Paris, France · ParisSanofi reports positive phase 3 results for oral venglustat in type 3 Gaucher disease, matching standard therapy outcomes and supporting plans for global regulatory filings.See the Story
Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials - Sanofi (NASDAQ:SNY)
60% Center coverage: 5 sources
